CA2086415C - Inhaler - Google Patents
InhalerInfo
- Publication number
- CA2086415C CA2086415C CA002086415A CA2086415A CA2086415C CA 2086415 C CA2086415 C CA 2086415C CA 002086415 A CA002086415 A CA 002086415A CA 2086415 A CA2086415 A CA 2086415A CA 2086415 C CA2086415 C CA 2086415C
- Authority
- CA
- Canada
- Prior art keywords
- metering member
- seat
- contact
- frusto
- cup
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0065—Inhalators with dosage or measuring devices
- A61M15/0068—Indicating or counting the number of dispensed doses or of remaining doses
- A61M15/007—Mechanical counters
- A61M15/0071—Mechanical counters having a display or indicator
- A61M15/0075—Mechanical counters having a display or indicator on a disc
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING OR COUNTING
- G06M—COUNTING MECHANISMS; COUNTING OF OBJECTS NOT OTHERWISE PROVIDED FOR
- G06M1/00—Design features of general application
- G06M1/22—Design features of general application for visual indication of the result of count on counting mechanisms, e.g. by window with magnifying lens
- G06M1/24—Drums; Dials; Pointers
- G06M1/246—Bands; Sheets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/062—Desiccants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Medicinal Preparation (AREA)
- Containers And Packaging Bodies Having A Special Means To Remove Contents (AREA)
- Steroid Compounds (AREA)
- External Artificial Organs (AREA)
Abstract
A novel inhaler is provided for delivering a substance in a finely divided form. The inhaler includes a body defining a storage chamber for the substance to be deliv-ered, and further defining an inhalation passage through which air is drawn via a mouthpiece. A metering member is operable to transfer a volumetric dose of the substance from the storage chamber to the inhalation passage, the metering member having a metering surface which provides at least one dispensing cup, and which is movable between a first position in which at least one dispensing cup is presented to the storage chamber to receive a dose of the substance, and a second position in which a dose of the substance is presented to the inhalation passage in the dispensing cup which is upwardly open in use. Cup clearing means is provided for ensuring that at least one dispensing cup is free from the substance before being presented to the storage chamber. The cup clearing means includes means for moving at least one dispensing cup into a position from which, in normal use of the inhaler, any of the substance remaining in the dispensing cup would tend to fall, under the influence of gravity, out of the dispensing cup, after a dose of the substance has been presented in the dispens-ing cup to the inhalation passage, and before the dispens-ing cup is again presented to the storage chamber.
Description
? ~
This invention relates to an inhaler, namely a device for use in delivering a dose of medicament or other sub-stance for inhaling into the lungs.
The most common form of inhaler propels the dose of medicament in pressurized gas from an aerosol. However, this form of inhaler is becoming less popular because of environmental and other considerations. The delivery of some drugs in a dry, finely divided form has been shown to have certain medical advantages over other forms of delivery.
Some known proposals for delivering medicament in a finely-divided form cannot be operated by one hand. It is considered that one-handed operation should be an important feature of such an inhaler.
EP 079478, EP 166294 and GB 2165159 all disclose dry powder inhalers which can be operated by one hand. In each of these proposals, the inhaler includes a medicament stor-age chamber and an inhalation passage through which air is drawn via a mouthpiece. A metering member, provided with a metering recess, transfers a dose of medicament from the storage chamber and deposits it in the inhalation chamber.
It is considered that the accuracy of such an arrangement can be very poor: on the one hand, by repeated indexing of the metering member it is possible to deposit two or more doses or medicament into the inhalation passage resulting in the administration of an overdose of medicament; on the other hand, since the medicament normally drops from the metering recess into the inhalation passage under gravity, ~' *
20~64 1 ~
particles of medicament can adhere to the interior of the metering recess so that an underdose is delivered.
U.S. Patent No. 2,587,215 also discloses dry powder inhalers with the same disadvantages as those mentioned above. However, this patent also discloses an embodiment in which the metering member presents the medicament in an upwardly-open dispensing cup to a mixing chamber where it is mixed with air before being sucked into an inhalation tube via a nozzle having a narrow opening. Air sucked into the inhaler passes into the inhalation tube, either directly or through the mixing chamber and nozzle.
Accordingly, not all the air passes over the dispensing cup. If medicament adheres to the surface of the dispens-ing cup but is not sucked therefrom, there will be an underdose of medicament delivered to the user. It is considered that, upon repeated use of the hollows to deliver doses to the inhalation passage, a continually increasing amount of the powder will adhere to the base of the hollow, resulting in progressively decreased dosage to the patient. The tendency for a build-up of adherent powder to occur is thought to be a source of inaccurate dosing in many of the inhalers previously proposed. The metering member is a rotary sliding device journalled on a cylindrical pivot member ext~n~;ng from the bottom of the body of the device. Such an arrangement is susceptible to jamming due to ingress of powder between the cylindrical contacting surfaces of the pivot member and the metering member.
~,..
r,.~
20 ~64 1 5 Another form of inhaler which is currently available includes a metering member including a number of tapered metering recesses which are open at top and bottom. In use, finely-divided medicament from a storage chamber is packed into the recesses whereupon the metering member is moved to a dispensing position in which air can be drawn through the recesses to draw out the medicament. This device is considered to have a number of major short-comings. Firstly, the metering recesses are prone to clogging. Secondly, a large amount of suction is required so that the device is unsuitable for many patients with breathing problems. Thirdly, two hands are required to operate the device.
The aim of the present invention may be viewed as being to provide a form of inhaler for one-handed operation which is capable of administering accurate doses and sub-stantially avoids the risk of multiple dosing. A further aim is to provide an inhaler which does not require a large amount of suction for effective operation.
The present invention, in one aspect thereof, provides an inhaler for delivering a substance in a finely divided form, comprising a body delivering a substance in a finely divided form, comprising: a body defining a storage chamber for the substance to be delivered, and further defining an inhalation passage through which air is drawn via a mouth-piece; a metering member operable to transfer a volumetric dose of the substance from the storage chamber to the inha-lation passage, the metering member having a metering sur-.
.
20864 ~ ~
face which is indented to provide one or more dispensing cups, and being movable between a first position in which at least one dispensing cup is presented to the storage chamber to receive a dose of the substance, and a second position in which a dose of the substance is presented to the inhalation passage in at least one dispensing cup which is upwardly open in use; and cup clearing means for ensur-ing that at least one dispensing cup is substantially free from the substance before being presented to the storage chamber, the cup clearing means comprising means for moving at least one dispensing cup into a position from which, in normal use of the inhaler, any of the substance remaining in that dispensing cup would tend to fall, under the influence of gravity, out of that dispensing cup, after a dose of the substance has been presented in that dispensing cup to the inhalation passage, and before that dispensing cup is again presented to the storage chamber.
Thus, in normal use of the inhaler, repeated indexing of the metering member will not deposit multiple doses of the substance into the inhalation passage. Furthermore, removal of the substance from the metering member by the inhaled air flow rather than under gravity can ensure that the dose is more thoroughly removed.
By one variant thereof, the cup clearing means may comprise an inhalation passage so formed that the dose of the substance presented to the inhalation passage is sub-jected to substantiall~ the entire airflow through the inhalation passage when air is drawn through the mouth-.~
This invention relates to an inhaler, namely a device for use in delivering a dose of medicament or other sub-stance for inhaling into the lungs.
The most common form of inhaler propels the dose of medicament in pressurized gas from an aerosol. However, this form of inhaler is becoming less popular because of environmental and other considerations. The delivery of some drugs in a dry, finely divided form has been shown to have certain medical advantages over other forms of delivery.
Some known proposals for delivering medicament in a finely-divided form cannot be operated by one hand. It is considered that one-handed operation should be an important feature of such an inhaler.
EP 079478, EP 166294 and GB 2165159 all disclose dry powder inhalers which can be operated by one hand. In each of these proposals, the inhaler includes a medicament stor-age chamber and an inhalation passage through which air is drawn via a mouthpiece. A metering member, provided with a metering recess, transfers a dose of medicament from the storage chamber and deposits it in the inhalation chamber.
It is considered that the accuracy of such an arrangement can be very poor: on the one hand, by repeated indexing of the metering member it is possible to deposit two or more doses or medicament into the inhalation passage resulting in the administration of an overdose of medicament; on the other hand, since the medicament normally drops from the metering recess into the inhalation passage under gravity, ~' *
20~64 1 ~
particles of medicament can adhere to the interior of the metering recess so that an underdose is delivered.
U.S. Patent No. 2,587,215 also discloses dry powder inhalers with the same disadvantages as those mentioned above. However, this patent also discloses an embodiment in which the metering member presents the medicament in an upwardly-open dispensing cup to a mixing chamber where it is mixed with air before being sucked into an inhalation tube via a nozzle having a narrow opening. Air sucked into the inhaler passes into the inhalation tube, either directly or through the mixing chamber and nozzle.
Accordingly, not all the air passes over the dispensing cup. If medicament adheres to the surface of the dispens-ing cup but is not sucked therefrom, there will be an underdose of medicament delivered to the user. It is considered that, upon repeated use of the hollows to deliver doses to the inhalation passage, a continually increasing amount of the powder will adhere to the base of the hollow, resulting in progressively decreased dosage to the patient. The tendency for a build-up of adherent powder to occur is thought to be a source of inaccurate dosing in many of the inhalers previously proposed. The metering member is a rotary sliding device journalled on a cylindrical pivot member ext~n~;ng from the bottom of the body of the device. Such an arrangement is susceptible to jamming due to ingress of powder between the cylindrical contacting surfaces of the pivot member and the metering member.
~,..
r,.~
20 ~64 1 5 Another form of inhaler which is currently available includes a metering member including a number of tapered metering recesses which are open at top and bottom. In use, finely-divided medicament from a storage chamber is packed into the recesses whereupon the metering member is moved to a dispensing position in which air can be drawn through the recesses to draw out the medicament. This device is considered to have a number of major short-comings. Firstly, the metering recesses are prone to clogging. Secondly, a large amount of suction is required so that the device is unsuitable for many patients with breathing problems. Thirdly, two hands are required to operate the device.
The aim of the present invention may be viewed as being to provide a form of inhaler for one-handed operation which is capable of administering accurate doses and sub-stantially avoids the risk of multiple dosing. A further aim is to provide an inhaler which does not require a large amount of suction for effective operation.
The present invention, in one aspect thereof, provides an inhaler for delivering a substance in a finely divided form, comprising a body delivering a substance in a finely divided form, comprising: a body defining a storage chamber for the substance to be delivered, and further defining an inhalation passage through which air is drawn via a mouth-piece; a metering member operable to transfer a volumetric dose of the substance from the storage chamber to the inha-lation passage, the metering member having a metering sur-.
.
20864 ~ ~
face which is indented to provide one or more dispensing cups, and being movable between a first position in which at least one dispensing cup is presented to the storage chamber to receive a dose of the substance, and a second position in which a dose of the substance is presented to the inhalation passage in at least one dispensing cup which is upwardly open in use; and cup clearing means for ensur-ing that at least one dispensing cup is substantially free from the substance before being presented to the storage chamber, the cup clearing means comprising means for moving at least one dispensing cup into a position from which, in normal use of the inhaler, any of the substance remaining in that dispensing cup would tend to fall, under the influence of gravity, out of that dispensing cup, after a dose of the substance has been presented in that dispensing cup to the inhalation passage, and before that dispensing cup is again presented to the storage chamber.
Thus, in normal use of the inhaler, repeated indexing of the metering member will not deposit multiple doses of the substance into the inhalation passage. Furthermore, removal of the substance from the metering member by the inhaled air flow rather than under gravity can ensure that the dose is more thoroughly removed.
By one variant thereof, the cup clearing means may comprise an inhalation passage so formed that the dose of the substance presented to the inhalation passage is sub-jected to substantiall~ the entire airflow through the inhalation passage when air is drawn through the mouth-.~
2~64 ~ 5 piece. Accordingly, by this variant, whether air is drawninto the inhaler through a single opening or through several openings, the airflow through the device is such that all the air flows along a single duct at the point where the dispensing cup is presented to the airflow within this duct.
By another variant thereof, the cup clearing means may additionally include resilient wiping means for dislodging any residual substance from a dispensing cup after a dose of the substance has been presented therein to the inhala-tion passage and before that cup is again presented to the storage chamber. The provision of such dislodging means ensures that a dispensing cup is cleaned prior to refill-ing, and thereby prevents a build-up of adherent material with repeated refills.
Preferably, by a variation of such variant, the metering member is resiliently biased into contact with a seat and is moveable while in contact with the seat. More preferably, by yet another variation, the metering member is rotatable while in contact with the seat.
By yet another variant thereof, the metering member may comprise a frusto-conical side wall containing the dispensing cup or cups. By a variation of such variant, suc~ a side wall can include a plurality of spaced-apart dispensing cups. The use of the frusto-conical shape in the wall of the metering member containing the dispensing cups allows a good seal to be obtained between the metering member and a seat against which the frusto-conical wall ~' .,~
6 20~4 1 5 mates. Accordingly, either rigid or semi-rigid plastics materials can be used, and the appropriate shapes can be manufactured with relatively undemanding tolerances. Other shapes, e.g., spherical or cylindrical shapes, either demand much tighter tolerances in order to achieve the sort of seal required or resilient materials would have to be used or, possible, an additional resilient sealing ring would have to be incorporated. The good seal referred to above should be such that the integrity of the stored drug is maintained by, for instance, preventing any ingress of moisture and/or contaminating air into the storage chamber.
The frusto-conical shape also makes it possible to form the metering member in such manner that it occupies relatively little space, so that the inhalation passage can be shorter than in many prior inhalers, reducing the amount of suction required from the patient.
Preferably, by yet another variation thereof, the longitudinal axis of the frusto-conical wall lies, when the inhaler is held in its normal in-use position, between ver-tical and an angle of 60 to the vertical. More prefer-abl~, by a variation thereof, this axis lies at an angle of about 45 to the vertical.
By still another variant thereof, the body of the inhaler preferably comprises a seat having an annular con-tact surface making sliding contact with the frusto-conical wall containing the dispensing cup or cups in which the body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of the .~ .
2 ~
metering member, the contact surface being correspondingly frusto-conical in shape so as to define a socket within which the metering member is journalled for rotation between its the first and the second positions. The inhaler then, by a variation thereof, preferably comprises means operable resiliently to bias the metering member into contact with the seat.
Preferably, by still another variant thereof, the inhaler includes a chamber for containing a moisture-absor-bent material, with which chamber a dispensing cup is move-able into register after a dose of the substance has been presented to the inhalation passage and before that cup is again presented to the storage chamber. In this way, the empty cup can be dried prior to filling to reduce adhesion of the surface in the cup. The filled dispensing cup may also move into register with the same or another chamber for moisture-absorbent material as it travels from the storage chamber to the inhalation passage. This could assist in preventing migration of moisture from the inhala-tion passage into the storage chamber.
By a still further variant thereof, the inhalerpreferably includes display means which is indexed in association with the metering member to display an item of information to the user. The display means may comprise counter means for counting the number of times which a dispensing cup has been presented to the inhalation pass-age, and/or the number of doses remaining to be so presented.
, 20~6~ ~ ~
As has been mentioned above, the provision of a frusto-conical shaped metering member is particularly advantageous in allowing greater manufacturing tolerances tha]~ would be possible with other configurations. If the metering member has a flat metering surface, as is the case in the above-described embodiment of U.S. Patent No.
2,587,215, then it is necessary to provide a separate axle or spigot journalled on a part of the device. Such a separate axle is susceptible to jamming by the ingress of powder between the contacting surfaces associated with the axle.
Having regard to this, another aspect of the present invention provides an inhaler for delivering a substance in a finely divided form, comprising a body defining a storage chamber for the substance to be delivered, and further defining an inhalation passage through which air is inhaled in use; and a metering member operable to transfer a volu-metric dose of the substance from the storage chamber to the inhalation passage, the metering member having a meter-ing surface which is indented to provide at least one dis-pensing cup and being moveable between a first position in which at least one dispensing cup is presented to the stor-age chamber to receive a dose of the substance, and a second position in which a dose of the substance is pre-sented to the inhalation passage in at least one dispensingcup which is upwardly open in use, the body comprising a seat having an annular contact surface making sliding contact with the metering surface, the metering surface .t--' 8a 2~6~1 ~
comprising a frusto-conical wall, and the contact surface being correspondingly frusto-conical in shape so as to define a socket within which the metering member is jour-nalled for rotation between its first and second positions.
Preferably, by a variant thereof, biassing means are provided resiliently to bias the metering member into con-tact with the seat.
By yet another variant thereof, in such an inhaler, the metering member preferably comprises a frusto-conical wall containing the dispensing cup or cups, the longi-tudinal axis of the frusto-conical wall lying, when the inhaler is held in its normal in-use position, between vertical and an angle of 60 to the vertical.
By a still further variant thereof, this inhaler may additionally include cup clearing means for ensuring that eacl~ dispensing cup is substantially-free from the sub-stance before being presented to the storage chamber. By one variation thereof, the cup clearing means may comprise means for moving a dispensing cup into a position from which, in normal use of the inhaler, any of the substance remaining in the dispensing cup would tend to fall, under the influence of gravity, out of the cup, after a dose of the substance has been presented in the cup to the inhal-ation passage and before that cup is again presented to thestorage chamber. Alternatively or additionally, by varia-tiOllS thereof, the cup clearing means may comprise an inhalation passage so formed that the dose of the substance 8b 20864 1 S
presented to the inhalation passage is subjected to sub-stantially the entire airflow through the inhalation pass-age when air is drawn into the inhaler in use, or may com-prise resilient wiping means for dislodging any residualsubstance from each cup after a dose of the substance has been presented therein to the inhalation passage and before that cup is again presented to the storage compartment.
In the accompanying drawings, Figure 1 is a general perspective view of an inhaler of one embodiment of the invention;
Figure 2 is a side view of the inhaler in use;
Figure 3 is a longitudinal section through the inhaler;
Figure 4 is section IV-IV of Figure 3;
Figures 5 and 6 are exploded perspective views of the inhaler viewed from opposite ends;
Figures 7a and 7b are exploded perspective view of the counter mechanism of the inhaler, again viewed from oppo-site ends; and Figures 8a and 8b show the assembled counter mechanismviewed from opposite ends.
As shown in the external views of Figures 1 and 2, the inhaler comprises a housing 1 which is provided with an air intake 2. A tubular mouthpiece 3 projects from the housing.
Referring to Figures 3 to 6, the housing contains an internal body 4 which, on its side remote from the mouth-pie~e 3, contains a recess 5 that provides a seat for a 8c 208~
met,ering member 6 which is rotatable about its axis in the recess. The metering member 6 includes a portion having a frusto-conical metering surface 7 which includes a series of circumferentially-arranged cup-like metering depressions 8. The recess 5 provides a seat of corresponding frusto-conical shape, the angular tolerance and circumferential form of the metering surface and of the seat being care-fully monitored in manufacture to ensure a close sliding contact between the two mating faces.
The opposite side of the body 4 includes a storage chamber 10 for a drug in the form of a micronized powder, the chamber 10 being arranged to register with one of the depressions 8. A second outer chamber 11 surrounds the storage chamber 10 for containing a moisture absorbing material such as silica gel granules. The second chamber 11 is open to the depressions 8 on both sides of the depression which is currently in register with the storage chamber 10, but the silica gel is prevented from migrating ~0 into the depressions ~y a-shaped ~ 092/00771 _ 9 _ 2 0 8 ~ ~15 PCT/GB91/01147 :
f~lter membrane 12. The same side of the body 4 further con~ains an inhalation passage 15 and a waste chamber 16, both of which register with one of the depressions 8. The inhalation passage 15 has a smooth internal contour and registers with both the air inlet 2 and the mouthpiece 3.
The air inlet 2 contains a filter membrane 17 for removing any contaminating particles that may be drawn into the inlet.
The waste chamber 16 contains a brush, a piece of sponge rubber or other flexible wiping element 18 which projects into the corresponding depression 8 to make wiping contact with t1he walls of the depression.
Referring more particularly to the inhalation passage 15, it can be seen from Fig 3 that, when the inhaler is in use, the inhalal:ion passage 15 extends in a downwards direction from the air intake 2, at least to the position where the dispensing cup 8 is presented to the inhalation passage.
The width of the i nh~ 1 Ation passage 15 is relatively large at the air intake, relatively small in the region of the dispensing cup and relatively large again at the mouthpiece 3. The inhalation passage includes a first relatively more-inclined portion ext~n~;ng generally downwardly from the air intake 2 to the dispensing cup 8 and a second relatively less-in,clined portion extending from the dispensing cup 8 to the mouthpiece 3. Dispensing cup 8 is situated on the outside of the bend linking these two portions of the inhalation passage. Opposite the dispensing cup, the wall of the inhalation passage bulges across the inhalation passage towards a dispensing cup to create a restricted passageway in the region of the dispensing cup. In this region, the shape of the inhalation passage results in the air being both accelerated and directed towards the dispensing cup so that there is a highly efficient pick-up of material from the cup.
,~
WO92/00771 10 PCT/GB91/01~
2 ~ 1 5 The frusto-conical head of the me~ering member 6 is secured to a co-axial circular ratchet formation 20 followed by a drum 21. A spring washer 22 acts between an end face of the drum 21 and the housing 1 to urge the metering member 6 against its seat in the recess 5. An i ~eYi ng button 25 projects from the housing 1 adjacent to the inlet 2 and is secured to an integral in~Ying finger 26 for engagement with the ratchet formation 20. A spring finger 27, again integral with the button 25, projects transversely of the i~Yi ng finger 26 to engage the internal body 4 and thus urge the button to project from the housing 1.
A tape 30 is wound into a roll 31 which is freely rotatable on a pin 32 projecting from the inside of the housing 1. The leading end of the tape 30 is secured to the drum 21, onto which it is wound from the roll 30 upon rotation of the metering member 6. The tape 30 is routed past a window 33 in the housing 1 through which a contiguous series of numbers or other information carried on the tape is displayed.
In use, the inhaler will normally be supplied as a sealed unit with the storage chamber 10 pre-filled with medicament or other substance in a dry, finely divided form. With the button 25 uppermost, the depression 8 which is in register with the storage chamber 10 will fill with a fixed volume of the medicament. With the inhaler held in one hand the mouthpiece 3 is inserted into the mouth as shown in Fig. 2 and the button 25 is depressed using the index finger so that the indexing element 26 causes the metering member 6 to rotate by one position, thus bringing the next, empty depression 8 into register with the storage chamber lO. At the same time a filled depression comes into register with the inhalation passage 15. Thus, when air is drawn through the inhalation passage 15 via the mouthpiece 3, the internal contours of the inhalation passage causes the air to impinge _~092/00771 1 1 PCT/GB91/01147 ~ 208~15 on the ma~erial still held in the depression 8, causing the powder to be mix into the air flow and, after passing through r the mouthpiece 3, enter the mouth and air passages of the user.
It should be noted that the powder in the depression 8 is subjec:ted to the entire airflow through the inh~l~tion passage 15, from the air intake 2 to the mouthpiece 3, which enables the user more readily to achieve a full dose, and also promotes substantially complete removal of the powder from the depression 8.
As the depressions travel around the axis of the metering member with successive indexing movements of the button 25, they l1ove past the wiping element 18 so that any residue of powder remaining in the depression is dislodged therefrom to fall into the waste chamber 16. Further travel of the depression causes it to move in register with the drying chamber ll so that the silica gel can absorb any moisture from the depression before it comes into register with the storage cham~er lO to be refilled with medicament. The filled depressions may also move in register with the drying chambe:r 12 to reduce the possibility of moisture migrating from t:he inhalation passage 15 to the storage chamber lO.
This may additionally ensure that the medicament remains dry, thereb~y ensuring that the vast majority of the medicament can be easily removed from the depression into the inhaled airflow.
It is important that the movement of a dose of powder to the dispensing position in the inhalation passage 15 is effected in such fashion as to maintain good sealing of the powder in the storage chamber lO, so that the integrity of the powder is preserved. This is facilitated by the provision of the frusto--conical shape of the metering surface 7 and of the WO92/00771 2 0 8 ~ 12 - PCT/GB91/01 ~
seat for it provided by the recess 5; such a shape makes it possible to achieve a good seal between the metering surface 7 and its seat with less demanding tolerances than are feasible when other Ch~p~c are used. Providing that the angular tolerance is maintained (which is relatively simple), other manufacturing tolerances are accommodated by the self-r^-l in~ arrangements of the metering surface 7 and the seat provided by the recess 5.
In normal use of the inhaler, repeated indexing of the metering member 6 will not deposit multiple doses of the substance into the i~hAlAtion passage. Instead, each dose will simply be carried round in the depression 8 until it is discarded into the waste chamber 16.
Each time the metering member is indexed, new information is carried into the window 33 by the tape 30. This information could simply be a number indicating how many doses have been used, or how many remain to be used, or both. The window could also display other information such as the time when the next dose should be taken.
Normally, the device will be disposed of once the inten~
number of doses has been used. It is, however, envisaged that the internal body 4 could contain a replaceable cartridge cont~;~;ng a fresh supply of medicament and possibly also fresh silica gel, new filters 12 and/or 17, and a fresh tape 31. This tape could be partially wound onto a replaceable drum 21 which engages the frusto-conical metering head 6.
A modified counting arrangement is shown in Figs 7 and 8.
The housing 1 contains a circular internal recess 36 which receives an outer ring 37 and an inner disc 38 which are arranged co-axially with the metering member 6. The disc 38 ~WO92/00771 13 2 0 8 6 4 1 S PCT/GB91/01147 carries the units 0 to 9 at 36~ intervals whereas the ring 37 is marked in multiples of tens at regular angular intervals. The tens and units are disposed so that they can both be displayed through a window 39 in the housing l. The 5 disc :38 is co~cted to, or driven by, the metering member 6 and carries an integral spring arm 40 which carries a pin 4l to act as a cam follower. Whenever the disc 38 completes one rotation, the arm 39 engages a cam 44 secured to the interior of th~ housing l, which causes the cam follower 41 to engage in on~ of a series of notches 45 around the outer periphery of the ring 37. This, in turn, indexes the ring by one angular position on each rotation of the disc 38. The number displayed in the window 40 can thus be incremented from, say, l to 200 to count the number of doses used.
Instead of a ring surrounding the disc 38, a second transparent disc could be disposed h~h; n~ the disc 38 so that the units are visible through the second disc, which again carries multiples of tens.
By another variant thereof, the cup clearing means may additionally include resilient wiping means for dislodging any residual substance from a dispensing cup after a dose of the substance has been presented therein to the inhala-tion passage and before that cup is again presented to the storage chamber. The provision of such dislodging means ensures that a dispensing cup is cleaned prior to refill-ing, and thereby prevents a build-up of adherent material with repeated refills.
Preferably, by a variation of such variant, the metering member is resiliently biased into contact with a seat and is moveable while in contact with the seat. More preferably, by yet another variation, the metering member is rotatable while in contact with the seat.
By yet another variant thereof, the metering member may comprise a frusto-conical side wall containing the dispensing cup or cups. By a variation of such variant, suc~ a side wall can include a plurality of spaced-apart dispensing cups. The use of the frusto-conical shape in the wall of the metering member containing the dispensing cups allows a good seal to be obtained between the metering member and a seat against which the frusto-conical wall ~' .,~
6 20~4 1 5 mates. Accordingly, either rigid or semi-rigid plastics materials can be used, and the appropriate shapes can be manufactured with relatively undemanding tolerances. Other shapes, e.g., spherical or cylindrical shapes, either demand much tighter tolerances in order to achieve the sort of seal required or resilient materials would have to be used or, possible, an additional resilient sealing ring would have to be incorporated. The good seal referred to above should be such that the integrity of the stored drug is maintained by, for instance, preventing any ingress of moisture and/or contaminating air into the storage chamber.
The frusto-conical shape also makes it possible to form the metering member in such manner that it occupies relatively little space, so that the inhalation passage can be shorter than in many prior inhalers, reducing the amount of suction required from the patient.
Preferably, by yet another variation thereof, the longitudinal axis of the frusto-conical wall lies, when the inhaler is held in its normal in-use position, between ver-tical and an angle of 60 to the vertical. More prefer-abl~, by a variation thereof, this axis lies at an angle of about 45 to the vertical.
By still another variant thereof, the body of the inhaler preferably comprises a seat having an annular con-tact surface making sliding contact with the frusto-conical wall containing the dispensing cup or cups in which the body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of the .~ .
2 ~
metering member, the contact surface being correspondingly frusto-conical in shape so as to define a socket within which the metering member is journalled for rotation between its the first and the second positions. The inhaler then, by a variation thereof, preferably comprises means operable resiliently to bias the metering member into contact with the seat.
Preferably, by still another variant thereof, the inhaler includes a chamber for containing a moisture-absor-bent material, with which chamber a dispensing cup is move-able into register after a dose of the substance has been presented to the inhalation passage and before that cup is again presented to the storage chamber. In this way, the empty cup can be dried prior to filling to reduce adhesion of the surface in the cup. The filled dispensing cup may also move into register with the same or another chamber for moisture-absorbent material as it travels from the storage chamber to the inhalation passage. This could assist in preventing migration of moisture from the inhala-tion passage into the storage chamber.
By a still further variant thereof, the inhalerpreferably includes display means which is indexed in association with the metering member to display an item of information to the user. The display means may comprise counter means for counting the number of times which a dispensing cup has been presented to the inhalation pass-age, and/or the number of doses remaining to be so presented.
, 20~6~ ~ ~
As has been mentioned above, the provision of a frusto-conical shaped metering member is particularly advantageous in allowing greater manufacturing tolerances tha]~ would be possible with other configurations. If the metering member has a flat metering surface, as is the case in the above-described embodiment of U.S. Patent No.
2,587,215, then it is necessary to provide a separate axle or spigot journalled on a part of the device. Such a separate axle is susceptible to jamming by the ingress of powder between the contacting surfaces associated with the axle.
Having regard to this, another aspect of the present invention provides an inhaler for delivering a substance in a finely divided form, comprising a body defining a storage chamber for the substance to be delivered, and further defining an inhalation passage through which air is inhaled in use; and a metering member operable to transfer a volu-metric dose of the substance from the storage chamber to the inhalation passage, the metering member having a meter-ing surface which is indented to provide at least one dis-pensing cup and being moveable between a first position in which at least one dispensing cup is presented to the stor-age chamber to receive a dose of the substance, and a second position in which a dose of the substance is pre-sented to the inhalation passage in at least one dispensingcup which is upwardly open in use, the body comprising a seat having an annular contact surface making sliding contact with the metering surface, the metering surface .t--' 8a 2~6~1 ~
comprising a frusto-conical wall, and the contact surface being correspondingly frusto-conical in shape so as to define a socket within which the metering member is jour-nalled for rotation between its first and second positions.
Preferably, by a variant thereof, biassing means are provided resiliently to bias the metering member into con-tact with the seat.
By yet another variant thereof, in such an inhaler, the metering member preferably comprises a frusto-conical wall containing the dispensing cup or cups, the longi-tudinal axis of the frusto-conical wall lying, when the inhaler is held in its normal in-use position, between vertical and an angle of 60 to the vertical.
By a still further variant thereof, this inhaler may additionally include cup clearing means for ensuring that eacl~ dispensing cup is substantially-free from the sub-stance before being presented to the storage chamber. By one variation thereof, the cup clearing means may comprise means for moving a dispensing cup into a position from which, in normal use of the inhaler, any of the substance remaining in the dispensing cup would tend to fall, under the influence of gravity, out of the cup, after a dose of the substance has been presented in the cup to the inhal-ation passage and before that cup is again presented to thestorage chamber. Alternatively or additionally, by varia-tiOllS thereof, the cup clearing means may comprise an inhalation passage so formed that the dose of the substance 8b 20864 1 S
presented to the inhalation passage is subjected to sub-stantially the entire airflow through the inhalation pass-age when air is drawn into the inhaler in use, or may com-prise resilient wiping means for dislodging any residualsubstance from each cup after a dose of the substance has been presented therein to the inhalation passage and before that cup is again presented to the storage compartment.
In the accompanying drawings, Figure 1 is a general perspective view of an inhaler of one embodiment of the invention;
Figure 2 is a side view of the inhaler in use;
Figure 3 is a longitudinal section through the inhaler;
Figure 4 is section IV-IV of Figure 3;
Figures 5 and 6 are exploded perspective views of the inhaler viewed from opposite ends;
Figures 7a and 7b are exploded perspective view of the counter mechanism of the inhaler, again viewed from oppo-site ends; and Figures 8a and 8b show the assembled counter mechanismviewed from opposite ends.
As shown in the external views of Figures 1 and 2, the inhaler comprises a housing 1 which is provided with an air intake 2. A tubular mouthpiece 3 projects from the housing.
Referring to Figures 3 to 6, the housing contains an internal body 4 which, on its side remote from the mouth-pie~e 3, contains a recess 5 that provides a seat for a 8c 208~
met,ering member 6 which is rotatable about its axis in the recess. The metering member 6 includes a portion having a frusto-conical metering surface 7 which includes a series of circumferentially-arranged cup-like metering depressions 8. The recess 5 provides a seat of corresponding frusto-conical shape, the angular tolerance and circumferential form of the metering surface and of the seat being care-fully monitored in manufacture to ensure a close sliding contact between the two mating faces.
The opposite side of the body 4 includes a storage chamber 10 for a drug in the form of a micronized powder, the chamber 10 being arranged to register with one of the depressions 8. A second outer chamber 11 surrounds the storage chamber 10 for containing a moisture absorbing material such as silica gel granules. The second chamber 11 is open to the depressions 8 on both sides of the depression which is currently in register with the storage chamber 10, but the silica gel is prevented from migrating ~0 into the depressions ~y a-shaped ~ 092/00771 _ 9 _ 2 0 8 ~ ~15 PCT/GB91/01147 :
f~lter membrane 12. The same side of the body 4 further con~ains an inhalation passage 15 and a waste chamber 16, both of which register with one of the depressions 8. The inhalation passage 15 has a smooth internal contour and registers with both the air inlet 2 and the mouthpiece 3.
The air inlet 2 contains a filter membrane 17 for removing any contaminating particles that may be drawn into the inlet.
The waste chamber 16 contains a brush, a piece of sponge rubber or other flexible wiping element 18 which projects into the corresponding depression 8 to make wiping contact with t1he walls of the depression.
Referring more particularly to the inhalation passage 15, it can be seen from Fig 3 that, when the inhaler is in use, the inhalal:ion passage 15 extends in a downwards direction from the air intake 2, at least to the position where the dispensing cup 8 is presented to the inhalation passage.
The width of the i nh~ 1 Ation passage 15 is relatively large at the air intake, relatively small in the region of the dispensing cup and relatively large again at the mouthpiece 3. The inhalation passage includes a first relatively more-inclined portion ext~n~;ng generally downwardly from the air intake 2 to the dispensing cup 8 and a second relatively less-in,clined portion extending from the dispensing cup 8 to the mouthpiece 3. Dispensing cup 8 is situated on the outside of the bend linking these two portions of the inhalation passage. Opposite the dispensing cup, the wall of the inhalation passage bulges across the inhalation passage towards a dispensing cup to create a restricted passageway in the region of the dispensing cup. In this region, the shape of the inhalation passage results in the air being both accelerated and directed towards the dispensing cup so that there is a highly efficient pick-up of material from the cup.
,~
WO92/00771 10 PCT/GB91/01~
2 ~ 1 5 The frusto-conical head of the me~ering member 6 is secured to a co-axial circular ratchet formation 20 followed by a drum 21. A spring washer 22 acts between an end face of the drum 21 and the housing 1 to urge the metering member 6 against its seat in the recess 5. An i ~eYi ng button 25 projects from the housing 1 adjacent to the inlet 2 and is secured to an integral in~Ying finger 26 for engagement with the ratchet formation 20. A spring finger 27, again integral with the button 25, projects transversely of the i~Yi ng finger 26 to engage the internal body 4 and thus urge the button to project from the housing 1.
A tape 30 is wound into a roll 31 which is freely rotatable on a pin 32 projecting from the inside of the housing 1. The leading end of the tape 30 is secured to the drum 21, onto which it is wound from the roll 30 upon rotation of the metering member 6. The tape 30 is routed past a window 33 in the housing 1 through which a contiguous series of numbers or other information carried on the tape is displayed.
In use, the inhaler will normally be supplied as a sealed unit with the storage chamber 10 pre-filled with medicament or other substance in a dry, finely divided form. With the button 25 uppermost, the depression 8 which is in register with the storage chamber 10 will fill with a fixed volume of the medicament. With the inhaler held in one hand the mouthpiece 3 is inserted into the mouth as shown in Fig. 2 and the button 25 is depressed using the index finger so that the indexing element 26 causes the metering member 6 to rotate by one position, thus bringing the next, empty depression 8 into register with the storage chamber lO. At the same time a filled depression comes into register with the inhalation passage 15. Thus, when air is drawn through the inhalation passage 15 via the mouthpiece 3, the internal contours of the inhalation passage causes the air to impinge _~092/00771 1 1 PCT/GB91/01147 ~ 208~15 on the ma~erial still held in the depression 8, causing the powder to be mix into the air flow and, after passing through r the mouthpiece 3, enter the mouth and air passages of the user.
It should be noted that the powder in the depression 8 is subjec:ted to the entire airflow through the inh~l~tion passage 15, from the air intake 2 to the mouthpiece 3, which enables the user more readily to achieve a full dose, and also promotes substantially complete removal of the powder from the depression 8.
As the depressions travel around the axis of the metering member with successive indexing movements of the button 25, they l1ove past the wiping element 18 so that any residue of powder remaining in the depression is dislodged therefrom to fall into the waste chamber 16. Further travel of the depression causes it to move in register with the drying chamber ll so that the silica gel can absorb any moisture from the depression before it comes into register with the storage cham~er lO to be refilled with medicament. The filled depressions may also move in register with the drying chambe:r 12 to reduce the possibility of moisture migrating from t:he inhalation passage 15 to the storage chamber lO.
This may additionally ensure that the medicament remains dry, thereb~y ensuring that the vast majority of the medicament can be easily removed from the depression into the inhaled airflow.
It is important that the movement of a dose of powder to the dispensing position in the inhalation passage 15 is effected in such fashion as to maintain good sealing of the powder in the storage chamber lO, so that the integrity of the powder is preserved. This is facilitated by the provision of the frusto--conical shape of the metering surface 7 and of the WO92/00771 2 0 8 ~ 12 - PCT/GB91/01 ~
seat for it provided by the recess 5; such a shape makes it possible to achieve a good seal between the metering surface 7 and its seat with less demanding tolerances than are feasible when other Ch~p~c are used. Providing that the angular tolerance is maintained (which is relatively simple), other manufacturing tolerances are accommodated by the self-r^-l in~ arrangements of the metering surface 7 and the seat provided by the recess 5.
In normal use of the inhaler, repeated indexing of the metering member 6 will not deposit multiple doses of the substance into the i~hAlAtion passage. Instead, each dose will simply be carried round in the depression 8 until it is discarded into the waste chamber 16.
Each time the metering member is indexed, new information is carried into the window 33 by the tape 30. This information could simply be a number indicating how many doses have been used, or how many remain to be used, or both. The window could also display other information such as the time when the next dose should be taken.
Normally, the device will be disposed of once the inten~
number of doses has been used. It is, however, envisaged that the internal body 4 could contain a replaceable cartridge cont~;~;ng a fresh supply of medicament and possibly also fresh silica gel, new filters 12 and/or 17, and a fresh tape 31. This tape could be partially wound onto a replaceable drum 21 which engages the frusto-conical metering head 6.
A modified counting arrangement is shown in Figs 7 and 8.
The housing 1 contains a circular internal recess 36 which receives an outer ring 37 and an inner disc 38 which are arranged co-axially with the metering member 6. The disc 38 ~WO92/00771 13 2 0 8 6 4 1 S PCT/GB91/01147 carries the units 0 to 9 at 36~ intervals whereas the ring 37 is marked in multiples of tens at regular angular intervals. The tens and units are disposed so that they can both be displayed through a window 39 in the housing l. The 5 disc :38 is co~cted to, or driven by, the metering member 6 and carries an integral spring arm 40 which carries a pin 4l to act as a cam follower. Whenever the disc 38 completes one rotation, the arm 39 engages a cam 44 secured to the interior of th~ housing l, which causes the cam follower 41 to engage in on~ of a series of notches 45 around the outer periphery of the ring 37. This, in turn, indexes the ring by one angular position on each rotation of the disc 38. The number displayed in the window 40 can thus be incremented from, say, l to 200 to count the number of doses used.
Instead of a ring surrounding the disc 38, a second transparent disc could be disposed h~h; n~ the disc 38 so that the units are visible through the second disc, which again carries multiples of tens.
Claims (27)
PROPERTY OR PRIVILEGE IS CLAIMED ARE DEFINED AS
FOLLOWS:
1. An inhaler for delivering a substance in a finely divided form, comprising: a body defining a storage chamber for said substance to be delivered, and further defining an inhalation passage through which air is drawn via a mouth-piece; a metering member operable to transfer a volumetric dose of said substance from said storage chamber to said inhalation passage, said metering member having a metering surface which is indented to provide at least one dispens-ing cup, and being movable between a first position in which at least one dispensing cup is presented to the storage chamber to receive a dose of the substance, and a second position in which a dose of the substance is pre-sented to said inhalation passage in said at least one dispensing cup which is upwardly open in use; and cup clearing means for ensuring that at least one said dispens-ing cup is substantially free from said substance before being presented to said storage chamber, said cup clearing means comprising means for moving said at least one dispensing cup into a position from which, in normal use of the inhaler, any of said substance remaining in said at least one dispensing cup would tend to fall, under the influence of gravity, out of said at least one dispensing cup, after a dose of said substance has been presented in said at least one dispensing cup to said inhalation passage, and before said at least one dispensing cup is again presented to said storage chamber.
2. An inhaler according to claim 1, in which said cup clearing means comprises an inhalation passage so formed that said dose of said substance presented to said inhalation passage is subjected to substantially the entire airflow through said inhalation passage when air is drawn through said mouthpiece.
3. An inhaler according to claim 1, in which said cup clearing means comprises resilient wiping means for dislodging any residual substance from said at least one dispensing cup after a dose of said substance has been presented therein to said inhalation passage and before said at least one dispensing cup is again presented to said storage chamber.
4. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat.
5. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, and further in which said metering member is rotatable while in contact with said seat.
6. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, and further in which said metering member com-prises a frusto-conical wall containing said dispensing cup or cups.
7. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member is rotat-able while in contact with said seat, and still further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups.
8. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, and still further in which the longitudinal axis of said frusto-conical wall lies, when said inhaler is held in its normal in-use position, between vertical and an angle of 60° to the vertical.
9. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member is rotat-able while in contact with said seat, still further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, and yet still fur-ther in which the longitudinal axis of said frusto-conical wall lies, when said inhaler is held in its normal in-use position, between vertical and an angle of 60° to the ver-tical.
10. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, and still further in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions.
11. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member is rotat-able while in contact with said seat, still further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, and yet still fur-ther in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions.
12. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, still further in which the longitudinal axis of said frusto-conical wall lies, when said inhaler is held in its normal in-use position, between vertical and an angle of 60° to the vertical, and yet still further in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions.
13. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member is rotat-able while in contact with said seat, still further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, still further in which the longitudinal axis of said frusto-conical wall lies, when said inhaler is held in its normal in-use posi-tion, between vertical and an angle of 60° to the vertical, and yet still further in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions.
14. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, still further in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions, and yet still further which includes biassing means operable resiliently to bias said metering member into contact with said seat.
15. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member is rotat-able while in contact with said seat, still further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, still further in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being corres-pondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rota-tion between its said first and said second positions, and yet still further which includes biassing means operable resiliently to bias said metering member into contact with said seat.
16. An inhaler according to claim 1, 2 or 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, still further in which the longitudinal axis of said frusto-conical wall lies, when said inhaler is held in its normal in-use position, between vertical and an angle of 60° to the vertical, still further in which said body com-prises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions, and yet still further which includes biassing means operable resiliently to bias said metering member into contact with said seat.
17. An inhaler according to claim 1, claim 2 or claim 3, in which said metering member is resiliently biased into contact with a seat, and is movable while in contact with said seat, further in which said metering member is rotat-able while in contact with said seat, still further in which said metering member comprises a frusto-conical wall containing said dispensing cup or cups, still further in which the longitudinal axis of said frusto-conical wall lies, when said inhaler is held in its normal in-use posi-tion, between vertical and an angle of 60° to the vertical, still further in which said body comprises a seat having an annular contact surface making sliding contact with the frusto-conical wall of said metering member, said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions, and yet still further includes biassing means operable resiliently to bias said metering member into contact with said seat.
18. An inhaler according to claim 1, claim 2 or claim 3 and having a chamber for containing moisture-absorbent material, with which chamber said at least one dispensing cup is moveable into register after said dose of said sub-stance has been presented to said inhalation passage, and before said at least one dispensing is again presented to said storage chamber.
19. An inhaler according to claim 1, claim 2 or claim 3, having a chamber for containing moisture-absorbent material, with which chamber said at least one dispensing cup is moveable into register after being presented to said storage chamber, and before said dose of said substance therein has been presented to said inhalation chamber.
20. An inhaler according to claim 1, claim 2 or claim 3 including display means which is indexed in association with said metering member to display an item of information to a user.
21. An inhaler for delivering a substance in a finely divided form, comprising: a body defining a storage chamber for said substance to be delivered, and further defining an inhalation passage through which air is inhaled in use; and a metering member operable to transfer a volumetric dose of said substance from said storage chamber to said inhalation passage, said metering member having a metering surface which is indented to provide at least one dispensing cup and being moveable between a first position in which said at least one dispensing cup is presented to said storage chamber to receive a dose of said substance, and a second position in which a dose of said substance is presented to said inhalation passage in said at least one dispensing cup which is upwardly open in use, said body comprising a seat having an annular contact surface making sliding contact with said metering surface, said metering surface compris-ing a frusto-conical wall, and said contact surface being correspondingly frusto-conical in shape so as to define a socket within which said metering member is journalled for rotation between its said first and said second positions.
22. An inhaler according to claim 21, comprising biassing means operable resiliently to bias said metering member into contact with said seat.
23. An inhaler according to claim 22 in which the longitudinal axis of said frusto-conical wall within which said metering surface comprises lies, when said inhaler is held in its normal in-use position, between vertical and an angle of 60° to the vertical.
24. An inhaler according to claim 21, claim 22 or claim 23, additionally comprising cup clearing means for ensuring that said at least one dispensing cup is substan-tially free from said substance before being presented to the storage chamber.
25. An inhaler according to claim 21, claim 22 or claim 23, additionally comprising cup clearing means for ensuring that said at least one dispensing cup is substantially free from said substance before being presented to the storage chamber, and further in which said cup clearing means comprises means for moving said at least one dispensing cup into a position from which, in normal use of said inhaler, any of said substance remaining in said at least one dispensing cup would tend to fall, under the influence of gravity, out of said at least one dispensing cup, after a said dose of said substance has been presented therein to said inhalation passage and before said at least one dispensing cup is again presented to said storage chamber.
26. An inhaler according to claim 21, claim 22 or claim 23, additionally comprising cup clearing means for ensuring that said at least one dispensing cup is substantially free from said substance before being presented to the storage chamber, and further in which said cup clearing means comprises an inhalation passage so formed that said dose of said substance presented to said inhalation passage is subjected to substantially the entire airflow through said inhalation passage when air is drawn into said inhaler in use.
27. An inhaler according to claim 21, claim 22 or claim 23, additionally comprising cup clearing means for ensuring that said at least one dispensing cup is substantially free from said substance before being presented to the storage chamber, further in which said cup clearing means comprises resilient wiping means for dislodging any residual substance from said at least one dispensing cup after a dose of said substance has been presented therein to said inhalation passage and before said at least one dispensing cup is again presented to said storage compartment.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB909015522A GB9015522D0 (en) | 1990-07-13 | 1990-07-13 | Inhaler |
GB9015522.7 | 1990-07-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2086415A1 CA2086415A1 (en) | 1992-01-14 |
CA2086415C true CA2086415C (en) | 1996-05-07 |
Family
ID=10679104
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002086415A Expired - Lifetime CA2086415C (en) | 1990-07-13 | 1991-07-11 | Inhaler |
Country Status (18)
Country | Link |
---|---|
US (2) | US5437270A (en) |
EP (2) | EP0539469B1 (en) |
JP (1) | JP2891541B2 (en) |
KR (1) | KR0184288B1 (en) |
AT (2) | ATE114981T1 (en) |
AU (1) | AU657914B2 (en) |
BR (1) | BR9106693A (en) |
CA (1) | CA2086415C (en) |
DE (2) | DE69108912T2 (en) |
DK (2) | DK0573128T3 (en) |
ES (2) | ES2068041T3 (en) |
FI (1) | FI104236B (en) |
GB (3) | GB9015522D0 (en) |
GR (2) | GR3015317T3 (en) |
NO (2) | NO304218B1 (en) |
NZ (2) | NZ248398A (en) |
WO (1) | WO1992000771A1 (en) |
ZA (1) | ZA915437B (en) |
Families Citing this family (228)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA26230A (en) * | 1990-03-02 | 1999-07-19 | Глексо Груп Лімітед | SHARED USER INHALATOR WITH TREATMENT UNIT AND TREATMENT UNIT |
SK280967B6 (en) | 1990-03-02 | 2000-10-09 | Glaxo Group Limited | Inhalation device |
US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
GB9004781D0 (en) * | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
GB9015522D0 (en) * | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
CA2093809A1 (en) * | 1991-08-15 | 1993-02-16 | Franco Del Bon | Inhaler |
JPH06509958A (en) * | 1991-08-26 | 1994-11-10 | ミネソタ マイニング アンド マニュファクチャリング カンパニー | powder dispenser |
US6119688A (en) * | 1991-08-26 | 2000-09-19 | 3M Innovative Properties Company | Powder dispenser |
GB9203761D0 (en) * | 1992-02-21 | 1992-04-08 | Innovata Biomed Ltd | Inhaler |
SE9201411D0 (en) * | 1992-05-05 | 1992-05-05 | Astra Ab | DOSAGE INHALATOR WITH INDICATING / INTERUPTING MEANS |
RU2107517C1 (en) * | 1992-09-11 | 1998-03-27 | Глэксо Груп Лимитед | Device for inhalation |
DE4239402A1 (en) * | 1992-11-24 | 1994-05-26 | Bayer Ag | Multiple dosage powder inhaler - has acceleration channel and dwell chamber for uniformly high drug dispersion |
AT398277B (en) * | 1992-12-11 | 1994-11-25 | Hurka Wilhelm | INHALATION DEVICE |
DE4340768A1 (en) * | 1993-11-30 | 1995-06-01 | Bayer Ag | Inhalation device |
DK0732952T3 (en) * | 1993-12-18 | 2000-09-25 | Merck Patent Gmbh | powder inhaler |
GB9326574D0 (en) * | 1993-12-31 | 1994-03-02 | King S College London | Dry power inhalers |
PT101450B (en) * | 1994-02-02 | 1999-11-30 | Hovione Produtos Farmaceuticos | NEW INHALATION DEVICE |
AU1752795A (en) * | 1994-03-10 | 1995-09-25 | Franco Del Bon | Inhalator |
FI942196A (en) | 1994-05-11 | 1995-11-12 | Orion Yhtymae Oy | powder inhaler |
FI95441C (en) * | 1994-05-31 | 1996-02-12 | Leiras Oy | Inhaler drug chamber |
JP3728753B2 (en) * | 1994-09-14 | 2005-12-21 | 株式会社デンソー | Deodorizing filter |
AU730625B2 (en) * | 1994-09-16 | 2001-03-08 | Laboratoire Glaxo Wellcome S.A. | Inhalation device |
MX9701957A (en) | 1994-09-16 | 1998-02-28 | Glaxo Wellcome Lab Sa | Inhalation device. |
SE9404140D0 (en) * | 1994-11-29 | 1994-11-29 | Astra Ab | Dose indicating device |
US5612053A (en) * | 1995-04-07 | 1997-03-18 | Edward Mendell Co., Inc. | Controlled release insufflation carrier for medicaments |
DK0820279T3 (en) * | 1995-04-14 | 2002-10-07 | Smithkline Beecham Corp | Dosing metered inhaler for Albuterol |
EP1166811B1 (en) * | 1995-04-14 | 2006-12-06 | SmithKline Beecham Corporation | Metered dose inhaler for fluticasone propionate |
US5622166A (en) * | 1995-04-24 | 1997-04-22 | Dura Pharmaceuticals, Inc. | Dry powder inhaler delivery system |
ATE209518T1 (en) * | 1995-06-21 | 2001-12-15 | Asta Medica Ag | MEDICINAL POWDER CARTRIDGE WITH INTEGRATED DOSING DEVICE AND POWDER INHALER |
FR2738152B1 (en) * | 1995-09-04 | 1998-01-23 | Tebro | POWDER PRODUCT PREDOSING DEVICE FOR A PRODUCT DISPENSER |
FR2738153B1 (en) * | 1995-09-04 | 1998-01-02 | Valois | INHALATION APPARATUS FOR DELIVERING PRECISE AND REPRODUCIBLE DOSES OF POWDERY PRODUCT |
FI102875B (en) * | 1995-11-10 | 1999-03-15 | Orion Yhtymae Oy | The powder inhaler |
US6123070A (en) * | 1996-06-07 | 2000-09-26 | Valois S.A. | Device for enhancing the emptying of an inhaler metering chamber |
DE19647947A1 (en) * | 1996-11-20 | 1998-05-28 | Pfeiffer Erich Gmbh & Co Kg | Discharge device for media |
GB9626263D0 (en) | 1996-12-18 | 1997-02-05 | Innovata Biomed Ltd | Powder inhaler |
GB2320489A (en) | 1996-12-20 | 1998-06-24 | Norton Healthcare Ltd | Inhaler dose counter |
TW469832U (en) | 1997-03-14 | 2001-12-21 | Astra Ab | Inhalation device |
SE9700938D0 (en) * | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhaler II and a method of construction thereof |
SE9700936D0 (en) * | 1997-03-14 | 1997-03-14 | Astra Ab | Inhalation device |
SE9700937D0 (en) | 1997-03-14 | 1997-03-14 | Astra Ab | Powder inhales I |
NL1006058C2 (en) * | 1997-05-14 | 1998-11-17 | R & D Injector Ag | Dosing device. |
TW533865U (en) * | 1997-06-10 | 2003-05-21 | Glaxo Group Ltd | Dispenser for dispensing medicament and actuation indicating device |
US6142339A (en) | 1998-01-16 | 2000-11-07 | 1263152 Ontario Inc. | Aerosol dispensing device |
CA2315777C (en) | 1998-01-16 | 2008-12-23 | 1263152 Ontario Inc. | Indicating device for use with a dispensing device |
US7143764B1 (en) | 1998-03-13 | 2006-12-05 | Astrazeneca Ab | Inhalation device |
US6336453B1 (en) | 1999-04-30 | 2002-01-08 | Trudell Medical International | Indicating device for aerosol container |
US6729330B2 (en) | 1998-05-05 | 2004-05-04 | Trudell Medical International | Indicating device for aerosol container |
US6082358A (en) | 1998-05-05 | 2000-07-04 | 1263152 Ontario Inc. | Indicating device for aerosol container |
DE19831525A1 (en) * | 1998-07-14 | 2000-01-20 | Pfeiffer Erich Gmbh & Co Kg | Media Donor |
FI107126B (en) * | 1999-04-23 | 2001-06-15 | Orion Yhtymae Oyj | Powder inhaler for combination medicine |
FI108518B (en) * | 1999-04-23 | 2002-02-15 | Orion Yhtymae Oyj | Powder inhaler for combination medicine |
ES2241611T3 (en) * | 1999-06-05 | 2005-11-01 | Innovata Biomed Limited | MEDICINES SUPPLY SYSTEM. |
US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
ES2165768B1 (en) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | NEW DERIVATIVES OF QUINUCLIDINE AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM. |
GB9920839D0 (en) | 1999-09-04 | 1999-11-10 | Innovata Biomed Ltd | Inhaler |
AU7290800A (en) | 1999-09-17 | 2001-04-24 | Orion Corporation | Moisture protected powder inhaler |
EP1220700B1 (en) * | 1999-10-06 | 2003-04-09 | Eckardt, Angela | Breathing-controlled inhalation device for dry powder |
GB9924949D0 (en) * | 1999-10-22 | 1999-12-22 | Innovata Biomed Ltd | Inhaler |
GB9928265D0 (en) * | 1999-12-01 | 2000-01-26 | Innovata Biomed Ltd | Inhaler |
EP1235605B1 (en) * | 1999-12-07 | 2005-06-01 | Orion Corporation | Multidose powder inhaler |
GB0003197D0 (en) * | 2000-02-11 | 2000-04-05 | Aid Medic Ltd | Improvements in and relating to controlling drug delivery |
AU2001234005B2 (en) | 2000-02-28 | 2006-01-19 | Pharmakodex Limited | Improvements in or relating to the delivery of oral drugs |
GB0005201D0 (en) * | 2000-03-04 | 2000-04-26 | Innovata Biomed Ltd | Tooling methods |
FI20000810A0 (en) * | 2000-04-06 | 2000-04-06 | Orion Yhtymae Oyj | The powder inhaler |
GB2364649A (en) * | 2000-05-17 | 2002-02-06 | Orion Corp | Inhaler with Dose Counter |
TWI224513B (en) | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Dose counter for medicament inhaler |
GB0019429D0 (en) | 2000-08-09 | 2000-09-27 | Innovata Biomed Ltd | Diaphragm |
GB0024793D0 (en) | 2000-10-10 | 2000-11-22 | Innovata Biomed Ltd | Diaphragm |
US20040050385A1 (en) * | 2000-10-20 | 2004-03-18 | Bonney Stanley George | Inhaler |
FI20002363A0 (en) * | 2000-10-27 | 2000-10-27 | Orion Yhtymae Oyj | powder inhaler |
PL365736A1 (en) * | 2001-02-06 | 2005-01-10 | Innovata Biomed Limited | Bimodal dry powder formulation for inhalation |
GB0111337D0 (en) | 2001-05-10 | 2001-07-04 | Innovata Biomed Ltd | Device |
GB0111336D0 (en) | 2001-05-10 | 2001-07-04 | Innovata Biomed Ltd | Device |
GB0111330D0 (en) | 2001-05-10 | 2001-07-04 | Innovata Biomed Ltd | Device |
US6745760B2 (en) | 2001-05-15 | 2004-06-08 | Trudell Medical International | Medicament applicator |
FI20011317A0 (en) | 2001-06-20 | 2001-06-20 | Orion Corp | The powder inhaler |
US6681768B2 (en) | 2001-06-22 | 2004-01-27 | Sofotec Gmbh & Co. Kg | Powder formulation disintegrating system and method for dry powder inhalers |
AUPR695801A0 (en) * | 2001-08-10 | 2001-09-06 | Caroma Industries Limited | An ultra-low volume gravity flushing toilet |
WO2003043905A2 (en) * | 2001-11-17 | 2003-05-30 | Aventis Pharma Limited | Pharmaceutical product with an adsorbent |
GB0128148D0 (en) | 2001-11-23 | 2002-01-16 | Innovata Biomed Ltd | Assembly |
GB0217199D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
GB0201677D0 (en) * | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
ES2300568T3 (en) | 2002-03-20 | 2008-06-16 | Mannkind Corporation | INHALATION APPARATUS |
US7004164B2 (en) | 2002-03-21 | 2006-02-28 | Trudell Medical International | Indicating device for aerosol container |
US7025205B2 (en) * | 2002-06-26 | 2006-04-11 | Aventis Pharma Limited | Method and packaging for pressurized containers |
US20050251289A1 (en) * | 2002-07-25 | 2005-11-10 | Bonney Stanley G | Medicament dispenser |
EP1534367A1 (en) * | 2002-07-25 | 2005-06-01 | Glaxo Group Limited | Medicament dispenser |
GB0217198D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
GB0217196D0 (en) * | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicament dispenser |
ATE503517T2 (en) | 2002-07-31 | 2011-04-15 | Chiesi Farma Spa | POWDER INHALER |
CA2694183C (en) | 2002-10-11 | 2013-06-25 | Otsuka Techno Corporation | Powder inhalator |
GB0315509D0 (en) * | 2003-07-02 | 2003-08-06 | Meridica Ltd | Dispensing device |
US7621273B2 (en) | 2003-10-28 | 2009-11-24 | Trudell Medical International | Indicating device with warning dosage indicator |
US7100530B2 (en) | 2003-12-15 | 2006-09-05 | Trudell Medical International, Inc. | Dose indicating device |
PT1730676E (en) * | 2004-02-16 | 2013-10-31 | Glaxo Group Ltd | Counter for use with a medicament dispenser |
WO2005102429A1 (en) * | 2004-04-21 | 2005-11-03 | Innovata Biomed Limited | Inhaler |
GB0409197D0 (en) | 2004-04-24 | 2004-05-26 | Innovata Biomed Ltd | Device |
PL1905451T3 (en) | 2004-05-31 | 2010-05-31 | Almirall Sa | Combinations comprising antimuscarinic agents and corticosteroids |
ES2257152B1 (en) | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | COMBINATIONS THAT INCLUDE ANTIMUSCARINIC AGENTS AND BETA-ADRENERGIC AGONISTS. |
KR101214823B1 (en) | 2004-07-16 | 2012-12-24 | 알미랄, 에스.에이. | Inhaler for the administration of powdered pharmaceuticals, and a powder cartridge system for use with this inhaler |
KR101166743B1 (en) * | 2004-08-12 | 2012-07-19 | 데이진 화-마 가부시키가이샤 | Counter mechanism of feeder and feeder having counter mechanism |
GB0418278D0 (en) * | 2004-08-16 | 2004-09-15 | Glaxo Group Ltd | Medicament dispenser |
MX2007001903A (en) | 2004-08-20 | 2007-08-02 | Mannkind Corp | Catalysis of diketopiperazine synthesis. |
KR101306384B1 (en) | 2004-08-23 | 2013-09-09 | 맨카인드 코포레이션 | Diketopiperazine salts, diketomorpholine salts or diketodioxane salts for drug delivery |
US7543582B2 (en) | 2004-09-20 | 2009-06-09 | Trudell Medical International | Dose indicating device with display elements attached to container |
WO2006062448A1 (en) * | 2004-12-10 | 2006-06-15 | Ernst Hörlins Ingenjörsbyrå Ab | Dose inhaler with a dose counter |
JP5189369B2 (en) | 2005-01-20 | 2013-04-24 | トルーデル メディカル インターナショナル | Dispensing device |
FR2883400B1 (en) | 2005-03-16 | 2007-06-15 | Valois Sas | DOSAGE INDICATING DEVICE FOR DISPENSING FLUID OR PULVERULENT PRODUCTS |
CN100431634C (en) * | 2005-04-04 | 2008-11-12 | 陈庆堂 | Dry powder aerosolizing inhalator |
US8524735B2 (en) | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
KR101488403B1 (en) | 2005-05-18 | 2015-02-04 | 엠펙스 파마슈티컬즈, 인코포레이티드 | Aerosolized fluoroquinolones and uses thereof |
ES2265276B1 (en) | 2005-05-20 | 2008-02-01 | Laboratorios Almirall S.A. | DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) Phenol as agonists of the BETA2 ADRENERGIC RECEIVER. |
JP5465878B2 (en) | 2005-09-14 | 2014-04-09 | マンカインド コーポレイション | Method of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents |
US20070068524A1 (en) * | 2005-09-28 | 2007-03-29 | Microdrug Ag | Inhaler for moisture sensitive drugs |
JP4934678B2 (en) | 2005-12-23 | 2012-05-16 | アストラゼネカ・アクチエボラーグ | New device |
US8865743B2 (en) * | 2006-01-06 | 2014-10-21 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8753308B2 (en) | 2006-01-06 | 2014-06-17 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8357114B2 (en) * | 2006-01-06 | 2013-01-22 | Acelrx Pharmaceuticals, Inc. | Drug dispensing device with flexible push rod |
US8252329B2 (en) * | 2007-01-05 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US9289583B2 (en) | 2006-01-06 | 2016-03-22 | Acelrx Pharmaceuticals, Inc. | Methods for administering small volume oral transmucosal dosage forms using a dispensing device |
US8202535B2 (en) | 2006-01-06 | 2012-06-19 | Acelrx Pharmaceuticals, Inc. | Small-volume oral transmucosal dosage forms |
US8535714B2 (en) | 2006-01-06 | 2013-09-17 | Acelrx Pharmaceuticals, Inc. | Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain |
US8252328B2 (en) * | 2006-01-06 | 2012-08-28 | Acelrx Pharmaceuticals, Inc. | Bioadhesive drug formulations for oral transmucosal delivery |
US9066847B2 (en) * | 2007-01-05 | 2015-06-30 | Aceirx Pharmaceuticals, Inc. | Storage and dispensing devices for administration of oral transmucosal dosage forms |
CN104383546B (en) | 2006-02-22 | 2021-03-02 | 曼金德公司 | Method for improving the pharmaceutical properties of microparticles comprising diketopiperazines and an active agent |
GB0605150D0 (en) * | 2006-03-14 | 2006-04-26 | Glaxo Group Ltd | Counter For Use With A Medicament Dispenser |
US8141550B2 (en) | 2006-08-01 | 2012-03-27 | Trudell Medical International | Dispensing device |
GB0622827D0 (en) | 2006-11-15 | 2006-12-27 | Glaxo Group Ltd | Sheet driver for use in a drug dispenser |
US20100139655A1 (en) * | 2006-11-19 | 2010-06-10 | Aespironics Ltd | Dry-powder inhaler |
BRPI0720846A2 (en) | 2006-12-22 | 2014-03-04 | Almirall Lab | INHALATION DEVICE FOR POWDERED DRUGS |
ES2306595B1 (en) | 2007-02-09 | 2009-09-11 | Laboratorios Almirall S.A. | NAPADISYLATE SALT OF 5- (2 - ((6- (2,2-DIFLUORO-2-PHENYLETOXI) HEXIL) AMINO) -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONE AS ADRENERGIC RECEIVER AGONIST BETA2 . |
ES2320955B1 (en) | 2007-03-02 | 2010-03-16 | Laboratorios Almirall S.A. | NEW DERIVATIVES OF 3 - ((1,2,4) TRIAZOLO (4,3-A) PIRIDIN-7-IL) BENZAMIDA. |
WO2009011782A2 (en) * | 2007-07-13 | 2009-01-22 | Abbott Biotechnology Ltd. | METHODS AND COMPOSITIONS FOR PULMONARY ADMINISTRATION OF A TNFa INHIBITOR |
WO2009046072A1 (en) * | 2007-10-02 | 2009-04-09 | Baxter International Inc | Dry powder inhaler |
ES2320961B1 (en) | 2007-11-28 | 2010-03-17 | Laboratorios Almirall, S.A. | DERIVATIVES OF 4- (2-AMINO-1-HYDROXYETHYL) PHENOL AS BETA2 ADRENERGIC RECEIVER AGONISTS. |
GB0800457D0 (en) | 2008-01-11 | 2008-02-20 | Innovata Biomed Ltd | Improvements in or relating to inhalers |
CA2716124A1 (en) * | 2008-02-20 | 2009-08-27 | Boehringer Ingelheim International Gmbh | Powder inhalers |
EP2096105A1 (en) | 2008-02-28 | 2009-09-02 | Laboratorios Almirall, S.A. | Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor |
EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
EP2108641A1 (en) | 2008-04-11 | 2009-10-14 | Laboratorios Almirall, S.A. | New substituted spiro[cycloalkyl-1,3'-indo]-2'(1'H)-one derivatives and their use as p38 mitogen-activated kinase inhibitors |
EP2113503A1 (en) | 2008-04-28 | 2009-11-04 | Laboratorios Almirall, S.A. | New substituted indolin-2-one derivatives and their use as p39 mitogen-activated kinase inhibitors |
US8082873B2 (en) | 2008-05-05 | 2011-12-27 | Trudell Medical International | Drive mechanism for an indicating device |
US8181591B1 (en) | 2008-05-23 | 2012-05-22 | Trudell Medical International | Domed actuator for indicating device |
US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
CN104689432B (en) | 2008-06-13 | 2018-07-06 | 曼金德公司 | Diskus and the system for drug conveying |
JP5479465B2 (en) | 2008-06-20 | 2014-04-23 | マンカインド コーポレイション | Interactive device and method for profiling inhalation efforts in real time |
TWI494123B (en) | 2008-08-11 | 2015-08-01 | Mannkind Corp | Use of ultrarapid acting insulin |
PL2346509T3 (en) | 2008-10-07 | 2021-03-08 | Horizon Orphan Llc | Inhalation of levofloxacin for reducing lung inflammation |
US8815838B2 (en) | 2008-10-07 | 2014-08-26 | David C. Griffith | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
EP2626098B1 (en) | 2008-10-22 | 2020-08-19 | Trudell Medical International | Modular aerosol delivery system |
US8945592B2 (en) | 2008-11-21 | 2015-02-03 | Acelrx Pharmaceuticals, Inc. | Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same |
EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
UY32297A (en) | 2008-12-22 | 2010-05-31 | Almirall Sa | MESILATE SALT OF 5- (2 - {[6- (2,2-DIFLUORO-2-PHENYLITOXI) HEXIL] AMINO} -1-HYDROXYETHYL) -8-HYDROXYCHINOLIN-2 (1H) -ONA AS A RECEIVER AGONIST B (BETA ) 2 ACRENERGIC |
US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
EP2221297A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one and its use in the treatment of pulmonary diseases |
EP2221055A1 (en) | 2009-02-18 | 2010-08-25 | Almirall, S.A. | 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one for the treatment of lung function |
EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
PL2405963T3 (en) | 2009-03-11 | 2014-04-30 | Mannkind Corp | Apparatus, system and method for measuring resistance of an inhaler |
EP2228368A1 (en) | 2009-03-12 | 2010-09-15 | Almirall, S.A. | Process for manufacturing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-hydroxyethyl)-8-hydroxyquinolin-2(1H)-one |
WO2010107761A1 (en) | 2009-03-18 | 2010-09-23 | Acelrx Pharmaceuticals, Inc. | Improved storage and dispensing devices for administration of oral transmucosal dosage forms |
US8985102B2 (en) | 2009-05-18 | 2015-03-24 | Adamis Pharmaceuticals Corporation | Dry powder inhalers |
EP2440184B1 (en) | 2009-06-12 | 2023-04-05 | MannKind Corporation | Diketopiperazine microparticles with defined specific surface areas |
MX353288B (en) | 2009-09-04 | 2018-01-08 | Raptor Pharmaceuticals Inc | Use of aerosolized levofloxacin for treating cystic fibrosis. |
WO2011056889A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
EP2322176A1 (en) | 2009-11-11 | 2011-05-18 | Almirall, S.A. | New 7-phenyl-[1,2,4]triazolo[4,3-a]pyridin-3(2H)-one derivatives |
US9492625B2 (en) | 2009-11-12 | 2016-11-15 | Stc.Unm | Dry powder inhaler with flutter dispersion member |
EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
EP2386555A1 (en) | 2010-05-13 | 2011-11-16 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activities |
EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
RU2571331C1 (en) | 2010-06-21 | 2015-12-20 | Маннкайнд Корпорейшн | Systems and methods for dry powder drug delivery |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
EP2457900A1 (en) | 2010-11-25 | 2012-05-30 | Almirall, S.A. | New pyrazole derivatives having CRTh2 antagonistic behaviour |
EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
US8561609B2 (en) | 2010-12-07 | 2013-10-22 | Respira Therapeutics, Inc. | Dry powder inhaler |
ES2913095T3 (en) | 2011-01-31 | 2022-05-31 | Avalyn Pharma Inc | Aerosolized pirfenidone and pyridone analog compounds and uses thereof |
EP2489663A1 (en) | 2011-02-16 | 2012-08-22 | Almirall, S.A. | Compounds as syk kinase inhibitors |
DK2694402T3 (en) | 2011-04-01 | 2017-07-03 | Mannkind Corp | BLISTER PACKAGE FOR PHARMACEUTICAL CYLINDER AMPULS |
EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
EP2518070A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Pyrrolotriazinone derivatives as PI3K inhibitors |
EP2518071A1 (en) | 2011-04-29 | 2012-10-31 | Almirall, S.A. | Imidazopyridine derivatives as PI3K inhibitors |
EP2527344A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | Pyridin-2(1H)-one derivatives useful as medicaments for the treatment of myeloproliferative disorders, transplant rejection, immune-mediated and inflammatory diseases |
EP2526945A1 (en) | 2011-05-25 | 2012-11-28 | Almirall, S.A. | New CRTH2 Antagonists |
WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
EP2548863A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists. |
EP2548876A1 (en) | 2011-07-18 | 2013-01-23 | Almirall, S.A. | New CRTh2 antagonists |
EP2554544A1 (en) | 2011-08-01 | 2013-02-06 | Almirall, S.A. | Pyridin-2(1h)-one derivatives as jak inhibitors |
EP2578570A1 (en) | 2011-10-07 | 2013-04-10 | Almirall, S.A. | Novel process for preparing 5-(2-{[6-(2,2-difluoro-2-phenylethoxy)hexyl]amino}-1(r)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one via novel intermediates of synthesis. |
AU2012328885B2 (en) | 2011-10-24 | 2017-08-31 | Mannkind Corporation | Methods and compositions for treating pain |
EP2592077A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
EP2592078A1 (en) | 2011-11-11 | 2013-05-15 | Almirall, S.A. | New cyclohexylamine derivatives having beta2 adrenergic agonist and M3 muscarinic antagonist activities |
GB2498746A (en) | 2012-01-26 | 2013-07-31 | Innovata Biomed Ltd | Inhaler which locks when empty |
WO2013114371A1 (en) | 2012-02-01 | 2013-08-08 | Protalix Ltd. | Dry powder formulations of dnase i |
GB2499597A (en) * | 2012-02-21 | 2013-08-28 | Innovata Biomed Ltd | Dry powder inhaler with stepped rotation of metering member |
US10463815B2 (en) | 2012-02-21 | 2019-11-05 | Respira Therapeutics, Inc. | Inhaler to deliver substances for prophylaxis or prevention of disease or injury caused by the inhalation of biological or chemical agents |
EP2641900A1 (en) | 2012-03-20 | 2013-09-25 | Almirall, S.A. | Novel polymorphic Crystal forms of 5-(2-{[6-(2,2-difluoro-2-phenylethoxy) hexyl]amino}-1-(R)-hydroxyethyl)-8-hydroxyquinolin-2(1h)-one, heminapadisylate as agonist of the ß2 adrenergic receptor. |
EP2647627A1 (en) | 2012-04-02 | 2013-10-09 | Almirall, S.A. | Salts of 5-[(1r)-2-({2-[4-(2,2-difluoro-2-phenylethoxy)phenyl] ethyl}amino)-1-hydroxyethyl]-8-hydroxyquinolin-2(1h)-one. |
EP2666465A1 (en) | 2012-05-25 | 2013-11-27 | Almirall, S.A. | Novel dosage and formulation |
EP2668941A1 (en) | 2012-05-31 | 2013-12-04 | Almirall, S.A. | Novel dosage form and formulation of abediterol |
AU2013289957B2 (en) | 2012-07-12 | 2017-02-23 | Mannkind Corporation | Dry powder drug delivery systems and methods |
WO2014060431A1 (en) | 2012-10-16 | 2014-04-24 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
EP2738172A1 (en) | 2012-11-28 | 2014-06-04 | Almirall, S.A. | New bicyclic compounds as crac channel modulators |
SG11201504452WA (en) | 2012-12-18 | 2015-07-30 | Almirall Sa | New cyclohexyl and quinuclidinyl carbamate derivatives having beta2 adrenergic agonist and m3 muscarinic antagonist activity |
TW201446767A (en) | 2013-02-15 | 2014-12-16 | Almirall Sa | Pyrrolotriazine derivatives as PI3K inhibitors |
EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
EP2848615A1 (en) | 2013-07-03 | 2015-03-18 | Almirall, S.A. | New pyrazole derivatives as CRAC channel modulators |
BR112016000937A8 (en) | 2013-07-18 | 2021-06-22 | Mannkind Corp | dry powder pharmaceutical formulations, method for making a dry powder formulation and use of a dry powder pharmaceutical formulation |
CA2919498C (en) | 2013-07-31 | 2023-07-25 | Windward Pharma, Inc. | Aerosol nintedanib compounds and uses thereof |
JP2016530930A (en) | 2013-08-05 | 2016-10-06 | マンカインド コーポレイション | Ventilation device and method |
WO2015091285A1 (en) | 2013-12-19 | 2015-06-25 | Almirall S.A. | Dosage formulation comprising salmeterol and fluticasone propionate |
WO2015106150A1 (en) | 2014-01-10 | 2015-07-16 | Genoa Pharmaceuticals Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
WO2015148905A1 (en) | 2014-03-28 | 2015-10-01 | Mannkind Corporation | Use of ultrarapid acting insulin |
US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
WO2016057693A1 (en) | 2014-10-10 | 2016-04-14 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for inhalation delivery of conjugated oligonucleotide |
MY187877A (en) | 2014-12-23 | 2021-10-26 | Acelrx Pharmaceuticals Inc | Systems, devices and methods for dispensing oral transmucosal dosage forms |
CA2972826C (en) | 2015-01-14 | 2023-09-12 | Respira Therapeutics, Inc. | Powder dispersion methods and devices |
WO2016170009A1 (en) | 2015-04-21 | 2016-10-27 | Almirall, S.A. | Amino-substituted heterocyclic derivatives as sodium channel inhibitors |
WO2016202800A1 (en) | 2015-06-16 | 2016-12-22 | Almirall, S.A. | Pyrrolotriazinone derivatives as pi3k inhibitors |
WO2017076990A1 (en) | 2015-11-05 | 2017-05-11 | Almirall, S.A. | Addition salts of n-[4-(4-{[(1s)-1-(5-methyl-4-oxo-3-phenyl-3,4-dihydropyrrolo[2,1-f][1,2,4]triazin-2-yl)ethyl]amino}-7h-pyrrolo[2,3-d]pyrimidin-5-yl)-1h-indol-6-yl]sulfamide |
CA3225148A1 (en) | 2016-05-19 | 2017-11-23 | Mannkind Corporation | Apparatus, system and method for detecting and monitoring inhalations |
TW201919682A (en) | 2017-08-08 | 2019-06-01 | 西班牙商阿爾米雷爾有限公司 | Novel compounds activating the Nrf2 pathway |
JP7455144B2 (en) | 2019-04-29 | 2024-03-25 | インスメッド インコーポレイテッド | Dry powder compositions of treprostinil prodrugs and methods of use thereof |
EP4065199B1 (en) | 2019-11-28 | 2024-01-03 | Chiesi Farmaceutici S.p.A. | Electronic module for an inhaler and inhaler assembly comprising the electronic module |
AU2020391939A1 (en) * | 2019-11-28 | 2022-06-02 | Chiesi Farmaceutici S.P.A. | Powder inhaler assembly |
WO2022240897A1 (en) | 2021-05-10 | 2022-11-17 | Sepelo Therapeutics, Llc | Pharmaceutical composition comprising delafloxacin for administration into the lung |
WO2023028364A1 (en) | 2021-08-27 | 2023-03-02 | Sepelo Therapeutics, Llc | Targeted compositions and uses therof |
WO2023150747A1 (en) | 2022-02-07 | 2023-08-10 | Insmed Incorporated | Dry powder compositions of bedaquiline and salts and methods of use thereof |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2587215A (en) * | 1949-04-27 | 1952-02-26 | Frank P Priestly | Inhalator |
DE2716323C2 (en) * | 1977-04-07 | 1986-03-13 | Schering AG, 1000 Berlin und 4709 Bergkamen | Device for inhalation of medicaments |
IT7920688V0 (en) * | 1979-02-05 | 1979-02-05 | Chiesi Paolo Parma | INHALER FOR PULVERULENT MEDICINAL SUBSTANCES, WITH COMBINED DOSER FUNCTION. |
US4274403A (en) * | 1979-08-29 | 1981-06-23 | Struve Roger L | Inhaler |
CY1492A (en) * | 1981-07-08 | 1990-02-16 | Draco Ab | Powder inhalator |
EP0079478A1 (en) * | 1981-11-03 | 1983-05-25 | Miles Laboratories, Inc. | Medicament inhalation device |
US4570630A (en) * | 1983-08-03 | 1986-02-18 | Miles Laboratories, Inc. | Medicament inhalation device |
SE448277B (en) * | 1985-04-12 | 1987-02-09 | Draco Ab | INDICATOR DEVICE WITH A DOSAGE DEVICE FOR MEDICINAL PRODUCTS |
US4811731A (en) * | 1985-07-30 | 1989-03-14 | Glaxo Group Limited | Devices for administering medicaments to patients |
GB9015522D0 (en) * | 1990-07-13 | 1990-08-29 | Braithwaite Philip W | Inhaler |
-
1990
- 1990-07-13 GB GB909015522A patent/GB9015522D0/en active Pending
-
1991
- 1991-07-11 DK DK93202365.8T patent/DK0573128T3/en active
- 1991-07-11 DE DE69108912T patent/DE69108912T2/en not_active Expired - Lifetime
- 1991-07-11 DK DK91913462.7T patent/DK0539469T3/en active
- 1991-07-11 ES ES93202365T patent/ES2068041T3/en not_active Expired - Lifetime
- 1991-07-11 BR BR919106693A patent/BR9106693A/en unknown
- 1991-07-11 KR KR1019930700026A patent/KR0184288B1/en not_active IP Right Cessation
- 1991-07-11 AT AT93202365T patent/ATE114981T1/en not_active IP Right Cessation
- 1991-07-11 AT AT91913462T patent/ATE120970T1/en not_active IP Right Cessation
- 1991-07-11 WO PCT/GB1991/001147 patent/WO1992000771A1/en active IP Right Grant
- 1991-07-11 JP JP3512226A patent/JP2891541B2/en not_active Expired - Lifetime
- 1991-07-11 EP EP91913462A patent/EP0539469B1/en not_active Expired - Lifetime
- 1991-07-11 ES ES91913462T patent/ES2072006T3/en not_active Expired - Lifetime
- 1991-07-11 AU AU81916/91A patent/AU657914B2/en not_active Expired
- 1991-07-11 DE DE69105756T patent/DE69105756T2/en not_active Expired - Lifetime
- 1991-07-11 EP EP93202365A patent/EP0573128B1/en not_active Expired - Lifetime
- 1991-07-11 CA CA002086415A patent/CA2086415C/en not_active Expired - Lifetime
- 1991-07-12 ZA ZA915437A patent/ZA915437B/en unknown
- 1991-07-12 NZ NZ248398A patent/NZ248398A/en not_active IP Right Cessation
- 1991-07-12 NZ NZ238958A patent/NZ238958A/en not_active IP Right Cessation
-
1992
- 1992-12-07 GB GB9225559A patent/GB2260498B/en not_active Expired - Lifetime
-
1993
- 1993-01-06 US US08/024,721 patent/US5437270A/en not_active Expired - Lifetime
- 1993-01-11 NO NO930084A patent/NO304218B1/en not_active IP Right Cessation
- 1993-01-12 FI FI930105A patent/FI104236B/en not_active IP Right Cessation
- 1993-06-01 GB GB9311259A patent/GB2265552B/en not_active Expired - Lifetime
-
1995
- 1995-02-03 US US08/383,002 patent/US5657748A/en not_active Expired - Lifetime
- 1995-03-03 GR GR950400495T patent/GR3015317T3/en unknown
- 1995-04-18 GR GR950400986T patent/GR3015854T3/en unknown
-
1998
- 1998-06-17 NO NO982791A patent/NO305467B1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2086415C (en) | Inhaler | |
JP4629947B2 (en) | Inhalation device with administration frequency counter | |
JP3132830B2 (en) | Multidose powder dispensing device | |
KR100976304B1 (en) | Powder Inhaler | |
EP0626869B1 (en) | Metering device | |
AU651910B2 (en) | Inhaler | |
IL100038A (en) | Inhalation device | |
JP2003516200A (en) | Multi-dose powder inhaler | |
EP1173242B1 (en) | Powder inhaler | |
WO1993025258A1 (en) | Inhaler | |
US20040123865A1 (en) | Powder inhaler | |
FI105654B (en) | Inhaling device | |
CA2085463C (en) | Device intended for measuring a dose of powdered medicament for inhalation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |